ACLARIS THERAPEUTICS INC.

- USD (-)

- 15 min delayed data - NASDAQ Stocks

Open:	-
Change:	-
Volume:	-

Low:	-
High:	-
High / Low range:	-

Type:	Stocks
Ticker:	ACRS
ISIN:

ACLARIS THERAPEUTICS INC. overview

> News PR Newswire published a news.

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets • • PR Newswire • Stocks • More ACLARIS THERAPEUTICS INC. news...

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets PR Newswire NEWARK, Del. and NANJING, China, Nov. 18, 2024 Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed $900M with tiered single digit...

Thank you Chart

> Analyses

Londinia AI has published a new analysis for nfkhamis.

0
85435
15269
0

ACLARIS THERAPEUTICS INC. - Daily

Timeframe : Daily - Simple chart
Status : INVALID

ACLARIS THERAPEUTICS INC. is currently trying to strengthen its basic trend with a very bullish short term. As long as the price remains above 1.26 USD, traders may consider taking advantage of this…

Thank you Reply Chart

> News PR Newswire published a news.

Thinking about buying stock in KE Holdings, Ford Motor, Vertiv Holdings, Cadrenal Therapeutics, or Aclaris Therapeutics? • • PR Newswire • Stocks • More ACLARIS THERAPEUTICS INC. news...

Thinking about buying stock in KE Holdings, Ford Motor, Vertiv Holdings, Cadrenal Therapeutics, or Aclaris Therapeutics? PR Newswire NEW YORK, Jan. 22, 2024 NEW YORK , Jan. 22, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BEKE, F, VRT, CVKD, and ACRS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. BEKE:...

Thank you Chart